According to a new market research study titled ‘Oligonucleotide Synthesis market – Global Analysis and Forecasts by Product, Application and End User. The global oligonucleotide synthesis market is expected to reach US$ 3,971.7 Mn in 2027 from US$ 1,584.2 Mn in 2018.
The market is estimated to grow with a CAGR of 11.1% from 2019-2027. The report highlights the trends prevalent in the global oligonucleotide synthesis market and the factors driving the market along with those that act as deterrents to its growth. The market is expected to grow due to increasing investments for synthetic biology and technological advancements genome editing tools.
Free | Get PDF Sample @ https://www.theinsightpartners.com/sample/TIPBT00002549/
Advancement in the field of biotechnology has equally enhanced the synthetic biology. Many industry players have come up with innovative types of synthetic biology in last few years. Synthetic biology is a multidisciplinary approach that use various tools and techniques of biotechnology to alter the biological systems. The techniques such as cloning, gene sequencing, genome engineering has results into the generation of genetically modified organisms. The advancement in the synthetic biology has led to the faster and easier design of DNA, and helped exponentially reducing the cost of DNA sequencing and synthesis.
Some of the players operating in oligonucleotide synthesis market are, Molecular Assemblies, Twist Bioscience, Evonetix, Nuclera Nucleics Ltd., Camena Bio, DNA Script, Iridia, Inc., Helixworks, Ansa Biotechnologies, Inc., and Synthomics, Inc., among others. The market players are focused towards bringing new and innovative products and services to sustain their position in the market. For instance, in October, 2018, EVONETIX LTD pioneering an innovative approach to scalable and high-fidelity gene synthesis, and LioniX International, a leading global provider of customised microsystem solutions in scalable production volumes, collaborated to scale up production of prototype microelectromechanical systems (MEMs) for DNA synthesis. The developments performed by the companies are helping the market to grow in the coming years.
The technological advancement as headed emergence of the New Bioeconomy, which is the replacement of petrochemical-based manufacturing and fermentation-based manufacturing products. In addition, the investments from public and private investors are rising for the synthetic biology. The rise in the investment are enabling technological developments and standard biological parts.
Ask For Discount @ https://www.theinsightpartners.com/discount/TIPBT00002549/
Oligonucleotides have many applications in research, diseases diagnosis, therapeutics, forensic, drug discovery, agriculture and many more. Oligonucleotides are used in many biological and forensic applications as sequence-specific binding agents can help in identifying presence of a specific target DNA sequence. Synthetic oligonucleotides are short stretches of single stranded DNA fragments assembled by chemical synthesis. There is hardly a field in biology in which synthetic DNA has not been used or does not have the potential to be used. The main reason for such a turnabout is the simultaneous developments of methods for the rapid and efficient synthesis of oligonucleotides and the advent of molecular biology techniques. Researchers are also using oligonucleotides to produce more efficient, greener chemical synthesis. By assembling oligonucleotides together into longer fragments that encode synthetic genes, bacteria or yeast cells can be instructed to produce specific enzymes (a type of protein). Oligonucleotides has tremendous potential for treating wide range of medical conditions. They enable the development of therapeutics as the malfunctioning genes can be targeted, manipulated, silenced and/or modulated. Ionis Pharmaceuticals has dedicated its existence to oligonucleotide therapeutic development, particularly antisense oligonucleotide (ASO) therapeutics. Thus, the promising potential of synthesized oligonucleotides in various fields drives the market growth.
Global oligonucleotide synthesis market, based on the end user was segmented into, academic research institutes, pharmaceutical & biotechnology companies, diagnostic laboratories, and other end users. Academic research institutes segment is anticipated to grow at a CAGR of 11.2% during the forecast period. The academic & research institutes are getting funds from the various organizations for the research and development sector for the betterment of gene synthesis Moreover, many of the organizations have formed due to the partnerships between various organizations and universities for research in the transformation of scientific technologies to make the life-saving treatments for patients.
Purchase this Report @ https://www.theinsightpartners.com/buy/TIPBT00002549/
Strategic Insights
Strategic acquisition and product launches were observed as the most adopted strategy in global oligonucleotide synthesis industry. Few of the recent product launch and acquisitions are listed below:
2018: Twist Bioscience has developed sample preparation products for customers performing next-generation sequencing experiments and analysis. The Twist Human Core Exome Kit includes all the tools needed for library construction, target capture and enrichment to prepare a sample for sequencing.
2018: Twist Bioscience Corporation expanded its North American operations with establishing a new office in San Diego area. The office supports sales and marketing and other corporate administrative functions and will be the headquarters for customer support for the company’s recently-launched solutions to enhance next-generation sequencing.
2018: EVONETIX LTD pioneering an innovative approach to scalable and high-fidelity gene synthesis, and LioniX International, a leading global provider of customised microsystem solutions in scalable production volumes, collaborated to scale up production of prototype microelectromechanical systems (MEMs) for DNA synthesis.
Contact Us:
Call: +1-646-491-9876
Email: sales@theinsightpartners.com